학술논문

Brain ageing in schizophrenia: evidence from 26 international cohorts via the ENIGMA Schizophrenia consortium
Document Type
Original Paper
Author
Constantinides, ConstantinosHan, Laura K. M.Alloza, ClaraAntonucci, Linda AntonellaArango, CelsoAyesa-Arriola, RosaBanaj, NerisaBertolino, AlessandroBorgwardt, StefanBruggemann, JasonBustillo, JuanBykhovski, OlegCalhoun, VinceCarr, VaughanCatts, StanleyChung, Young-ChulCrespo-Facorro, BenedictoDíaz-Caneja, Covadonga M.Donohoe, GaryPlessis, Stefan DuEdmond, JesseEhrlich, StefanEmsley, RobinEyler, Lisa T.Fuentes-Claramonte, PaolaGeorgiadis, FoivosGreen, MelissaGuerrero-Pedraza, AmaliaHa, MinjiHahn, TimHenskens, Frans A.Holleran, LaurenaHoman, StephanieHoman, PhilippJahanshad, NedaJanssen, JoostJi, EllenKaiser, StefanKaleda, VasilyKim, MinahKim, Woo-SungKirschner, MatthiasKochunov, PeterKwak, Yoo BinKwon, Jun SooLebedeva, IrinaLiu, JingyuMitchie, PatriciaMichielse, StijnMothersill, DavidMowry, Bryande la Foz, Víctor Ortiz-GarcíaPantelis, ChristosPergola, GiulioPiras, FabrizioPomarol-Clotet, EdithPreda, AdrianQuidé, YannRasser, Paul E.Rootes-Murdy, KellySalvador, RaymondSangiuliano, MarinaSarró, SalvadorSchall, UlrichSchmidt, AndréScott, Rodney J.Selvaggi, PierluigiSim, KangSkoch, AntoninSpalletta, GianfrancoSpaniel, FilipThomopoulos, Sophia I.Tomecek, DavidTomyshev, Alexander S.Tordesillas-Gutiérrez, Dianavan Amelsvoort, ThereseVázquez-Bourgon, JavierVecchio, DanielaVoineskos, AristotleWeickert, Cynthia S.Weickert, ThomasThompson, Paul M.Schmaal, Liannevan Erp, Theo G. M.Turner, JessicaCole, James H.Dima, DanaiWalton, Esther
Source
Molecular Psychiatry. 28(3):1201-1209
Subject
Language
English
ISSN
1359-4184
1476-5578
Abstract
Schizophrenia (SZ) is associated with an increased risk of life-long cognitive impairments, age-related chronic disease, and premature mortality. We investigated evidence for advanced brain ageing in adult SZ patients, and whether this was associated with clinical characteristics in a prospective meta-analytic study conducted by the ENIGMA Schizophrenia Working Group. The study included data from 26 cohorts worldwide, with a total of 2803 SZ patients (mean age 34.2 years; range 18–72 years; 67% male) and 2598 healthy controls (mean age 33.8 years, range 18–73 years, 55% male). Brain-predicted age was individually estimated using a model trained on independent data based on 68 measures of cortical thickness and surface area, 7 subcortical volumes, lateral ventricular volumes and total intracranial volume, all derived from T1-weighted brain magnetic resonance imaging (MRI) scans. Deviations from a healthy brain ageing trajectory were assessed by the difference between brain-predicted age and chronological age (brain-predicted age difference [brain-PAD]). On average, SZ patients showed a higher brain-PAD of +3.55 years (95% CI: 2.91, 4.19; I2 = 57.53%) compared to controls, after adjusting for age, sex and site (Cohen’s d = 0.48). Among SZ patients, brain-PAD was not associated with specific clinical characteristics (age of onset, duration of illness, symptom severity, or antipsychotic use and dose). This large-scale collaborative study suggests advanced structural brain ageing in SZ. Longitudinal studies of SZ and a range of mental and somatic health outcomes will help to further evaluate the clinical implications of increased brain-PAD and its ability to be influenced by interventions.